Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri

• Published in: International ophthalmology Vol. 29; no. 3; pp. 183 - 185
• Main Authors: Jamerson, Scott C., Arunagiri, Guruswami, Ellis, Brian D., Leys, Monique J.
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.06.2009; Springer Nature B.V
• Subjects: Acetazolamide - administration & dosage; Adult; Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Bevacizumab; Case Report; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - etiology; Choroidal Neovascularization - physiopathology; Diuretics - administration & dosage; Drug Administration Schedule; Female; Humans; Medicine; Medicine & Public Health; Ophthalmology; Papilledema - etiology; Pseudotumor Cerebri - complications; Pseudotumor Cerebri - drug therapy; Pseudotumor Cerebri - physiopathology; Pupil Disorders - etiology; Treatment Outcome; Visual Acuity; Visual Fields; Pseudotumor cerebri; Choroidal neovascularization; Bevacizumab
• ISSN: 0165-5701; 1573-2630
• DOI: 10.1007/s10792-007-9186-y

Background In pseudotumor cerebri (PTC), elevated intracranial pressure (ICP) results in papilledema and, rarely, choroidal neovascularization (CNV). Pseudotumor cerebri-induced CNV often regresses following medical or surgical ICP reduction, but additional treatments, such as photocoagulation, photodynamic therapy, peri-ocular steroid injections and/or subretinal surgery, may be necessary. Anti-angiogenic intravitreal injections have been shown to cause regression of both CNV and optic nerve edema. Case report We describe a patient with PTC and CNV whose CNV regressed and vision normalized after a single intravitreal injection of bevacizumab (Avastin; Genentech, San Francisco, CA).